medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2009, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2009; 8 (2)


The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation

Cadden ISH, Greanya ED, Erb SR, Scudamore CH, Yoshida EM

Idioma: Ingles.
Referencias bibliográficas: 34
Paginas: 158-161
Archivo PDF: 39.83 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361: 1533-44.

  2. Strange JW, Wharton J, Phillips PG, Wilkins MR. Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin Sci 2002; 102: 253-68.

  3. Lebrec D, Capron JP, Dhumeaux D, Benhamou JP. Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis 1979; 120: 849-56.

  4. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127: 437-41.

  5. Hadengue A, Benhayou MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520-8.

  6. Yang YY, Lin HC, Lee WC, Hou MC, Lee FY, Chang FY, et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol 2001; 36: 181-6.

  7. Michael AE, Ramsay B, Simpson R, Nguyen AT, Ramsay KG, East C, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transplant Surg 1997; 3: 494-500.

  8. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-450.

  9. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, et al. Frequency and clinical implications of increased pulmonary pressure in liver transplant patients. Mayo Clin Proc 1996; 71: 543-51.

  10. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, et al. Pulmonary vascular disorder in portal hypertension. Eur Respir J 1998; 11: 1153-66.

  11. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492-8.

  12. Halank M, Ewert R, Seyfarth HJ, Hoeffken G. Portopulmonary hypertension. J Gastroenterol 2006; 41: 837-847.

  13. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA et al. Screening, early detection and diagnosis of pulmonary arterial hypertension. Chest 2004; 126: 14S-34S.

  14. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation : a prospective study. Hepatology 2003; 37: 401-9.

  15. Csete M. Intraoperative management of liver transplant patients with pulmonary hypertension. Liver Transpl Surg 1997; 3: 454-455.

  16. Mandell MS, Krowka MJ. Formation of a national database on pulmonary hypertension and hepatopulmonary syndrome in chronic liver disease. Anesthesiology 1997; 87: 450-451.

  17. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KT, East C, Klintman GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3: 494-500.

  18. Mandell MS, Groves BM. Pulmonary hypertension in liver disease. Clin Chest Med 1996; 17: 17-33.

  19. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. New Engl J Med 1992; 327: 76-81.

  20. Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998; 65: 457-9.

  21. Krowka MJ, Mandell MS, Ramsay MAE, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transp 2004; 10: 174-82.

  22. Wang YW, Lin HC, Yang YY, Hou MC, Lee SD. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. J Gastroenterol 2006; 41: 593-597.

  23. Schroeder RA, Rafii AA, Plotkin JS, Johnson LB, Rustgi VK, Kuo PC. Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. Transplantation 2000; 70: 548-50.

  24. Halank M, Marx C, Miehlke S, Hoeffken G. Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol 2004; 39: 1222-3.

  25. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J et al. Bosentan therapy for portopulmonary hypertension. Eur Resp J 2005; 25: 502-8.

  26. Halank M, Miehlke S, Hoffken G, Schmeisser A, Schulze M, Strasser RH. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004; 77: 1775-6.

  27. Hinterhuber L, Graziadei IW, Kahler CM, Jaschke W, Vogel W. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004; 2: 1039-42.

  28. Rubin LJ, Badesch DB, Barst R, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.

  29. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for the portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transplantation 2004; 10: 945-950.

  30. Chua R, Keogh A, Miyashita M. Novel use of Sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 2005; 24: 498-500.

  31. Callejas-Rubio JL, Salmeron-Escobar J, Gonzalez-Calvin J, Ortego-Centeno N. Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil. Liver Transpl 2006; 12: 690-1.

  32. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H et al. Sildenafil treatment for portopulmonary hypertension. Eur Resp J 2006; 28: 563-7.

  33. Colle I, De Vriese AS, Van Vlierberghe H, Lameire NH, De Vos M. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int 2004; 24: 63-8.

  34. Charalabos T, Ageliki C, Spiros D. Sildenafil (Viagra) is a risk factor for acute variceal bleeding. Am J Gastroenterol 2002; 97: 1856.




2020     |     www.medigraphic.com